UnitedHealth’s third-quarter earnings from operations rose, and management raised its 2026 adjusted earnings outlook.
Optum generated big third-quarter revenue and serves over 120 million patients and consumers, giving UnitedHealth growth exposure beyond insurance.
Three 2031 scenarios for UnitedHealth assume annual earnings growth of between 8% and 16%, including management’s long-term target range.
UnitedHealth Group (NYSE: UNH) is setting ambitious long-term growth targets, which it reiterated on its Oct. 13 earnings call. Looking ahead, with its turnaround gaining traction and Optum creating new growth opportunities, how much upside could UNH shares have by 2031?
Image source: Getty Images.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
These days, UnitedHealth is showing signs that its turnaround strategy is working. Indeed, after a difficult stretch marked by rising medical costs, operational challenges, and pressure on profitability, the healthcare giant is making progress in improving its earnings growth.
For example, in the third quarter of 2026, revenue reached $112.7 billion, while adjusted earnings came in at $4.69 per share, beating analyst expectations. More importantly, operating earnings increased to $6.6 billion from $4.3 billion year over year. On top of that, management raised its full-year 2026 adjusted earnings guidance to at least $20.50 per share.
Perhaps the most interesting development for long-term investors came during the company's October earnings call. Specifically, the company reiterated its long-term earnings growth target of 13% to 16%, adding that management considers the lower end of that range a reasonable starting point for 2027.
That means, if management can deliver on those targets, earnings could compound significantly over the next five years, giving the stock considerable upside.
One reason to be optimistic about UnitedHealth's longer-term growth is its Optum business, which provides exposure to far more than traditional health insurance.
Specifically, Optum combines healthcare delivery, pharmacy services, and data analytics, creating several opportunities to generate revenue across different parts of the healthcare system while helping UnitedHealth manage costs within its insurance operations.
Meanwhile, Optum Health provides exposure to value-based care. Instead of charging for individual medical procedures, this model focuses on managing patients' overall health outcomes while controlling the total cost of care. In turn, that creates an opportunity for UnitedHealth to benefit from more efficient healthcare delivery and improved patient outcomes.
Plus, Optum Insight offers attractive opportunities through its healthcare technology and data capabilities, using artificial intelligence (AI) and automation to unlock further growth. In fact, management noted that AI-enabled chart summarization had expanded to more than 40% of employed clinicians, reducing chart review time by around 33%.
Despite the improving outlook, the company still faces meaningful risks. For one, medical costs could continue to rise, especially for senior and complex patients, making it harder to improve margins. Plus, the company is exposed to changes in Medicare Advantage reimbursement, regulatory scrutiny, and pressure on its pharmacy benefit management operations.
Ultimately, UnitedHealth's ability to turn improvements into consistent earnings growth will determine just how much upside the stock has over the next five years.
Management's long-term earnings growth target of 13% to 16% is a useful starting point. Using its 2026 adjusted earnings per share (EPS) guidance of $20.50, UnitedHealth could grow earnings to around $37.77 per share by 2031 under the base case, assuming 13% annual growth. If it achieves the upper end of its target, EPS could reach around $43.06.
Right now, UnitedHealth trades at a forward price-to-earnings (P/E) ratio of about 17. From there, if P/E grows modestly to about 18.5 times under the base case, the target price could reach $699, suggesting the stock could increase 71.5%.
Conservatively, 8% annual growth would lift EPS to around $30.12 by 2031, and a P/E of 14 would imply $422, or 3.5% upside.
Finally, under the bull case, its P/E could expand to 22 times, pushing the target price to $947, implying a potential upside of 132.4%.
Perhaps a higher valuation could be justified if Optum continues to expand its higher-value healthcare services and technology operations, AI investments drive productivity gains, and Medicare Advantage continues to see earnings recovery.
| Scenario | Annual earnings growth | 2031 EPS | 2031 P/E | Target price | Upside vs. last close |
|---|---|---|---|---|---|
| Conservative | 8% | Around $30.12 | 14 | $422 | 3.5% |
| Base | 13% | Around $37.77 | 18.5 | $699 | 71.5% |
| Bull (optimistic) | 16% | Around $43.06 | 22 | $947 | 132.4% |
Data source: Calculations by the author.
Of course, these are scenarios, not promises, so where the stock lands by 2031 could differ. But together, the catalysts could convince investors that UnitedHealth deserves a higher valuation than a traditional health insurer does.
Before you buy stock in UnitedHealth Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*
Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 18, 2026.
Rick Orford has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.